Financial Data and Key Metrics Changes - Total operating expenses for Q4 2025 were $15.4 million, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year [18] - Research and development expenses were $41.1 million for fiscal year 2025, down from $50.5 million in fiscal year 2024, representing a decrease of 19% [18] - General and administrative expenses were $25.7 million for fiscal year 2025, compared to $31.0 million in fiscal year 2024, a decrease of 17% [19] - Cash burn in 2025 was $50.2 million, down from $57.8 million in 2024 [21] - The company ended the quarter with $156.1 million in cash equivalents and investments [20] Business Line Data and Key Metrics Changes - The early access program for the tau proteoform assay was launched in January 2026, with initial customer engagements primarily with academic key opinion leaders [22] - The company anticipates modest services revenue later in 2026, with a primary revenue ramp expected to begin in 2027 once instruments start shipping [22] Market Data and Key Metrics Changes - The company is expanding its proteoform capabilities into additional high-value disease targets, including a collaboration focused on alpha-synuclein proteoforms in Parkinson's disease [8][15] - The oncology market is identified as a compelling next opportunity, with plans to evaluate multiple oncology-focused candidate proteins [15] Company Strategy and Development Direction - Nautilus aims to transition from development to active customer engagement, focusing on commercialization and external validation [5][9] - The company plans to progress early access customers into tau services projects and expand early access to include a second proteoform assay focused on an oncology target [25] - The Voyager instrument is expected to be commercially launched in late 2026, with pre-orders opening and installations beginning in early 2027 [25] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the technical foundation required to scale assays and broaden the target portfolio, supporting future commercial deployment [17] - The company expects total operating expenses for 2026 to increase by approximately 15%-20% as it continues investing in platform development [21] - Management highlighted the importance of collaborations and external validation in demonstrating the platform's relevance and potential impact [12][16] Other Important Information - The company has received grant funding from the Michael J. Fox Foundation, expected to total approximately $1.2 million, to support the development of an alpha-synuclein proteoform assay [23] - Nautilus's proprietary Iterative Mapping methodology is designed to analyze single, intact protein molecules at scale, aiming to unlock new biological insights [4][5] Q&A Session Summary Question: What are the next milestones and metrics that will improve based on Q4 technical achievements? - Management highlighted the completion of the tau proteoform assay studies and shared data with early customers, who expressed excitement about the assay's quality [29] Question: Will there be any revenue from the commercial launch later this year? - Management anticipates modest services revenue later in 2026, with a target of around half a million dollars for 2026, while the main revenue ramp will occur in 2027 [39] Question: How is the early access program progressing and what feedback has been received? - Feedback from early customers has been positive, with excitement about the data quality and the ability to forge connections in research that were previously unattainable [42]

Core Insights - The presentation aims to provide an overview of the company's advancements in proteomics and the associated challenges in understanding the complexity of the proteome [1] - The focus is on the Proteus program, which represents the majority of the company's R&D investment, highlighting its significance in enhancing performance [1] Group 1: Technology and R&D - The company is investing heavily in the Proteus program, which is central to its current R&D efforts [1] - There are also modest investments in long-term technology development, indicating a balanced approach to immediate and future innovations [1] Group 2: Future Developments - Upcoming discussions will include plans to expand to 20 amino acids, with details on the timeline for achieving this goal [2]

Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease from $21.6 million in Q1 2024, reflecting a focus on cost efficiency [28] - Research and development expenses decreased to $11.5 million from $12.9 million year-over-year [28] - General and administrative expenses were $7.3 million in Q1 2025, down from $8.7 million in the prior year [29] - Overall net loss for Q1 2025 was $16.6 million, compared to $18.7 million in the prior year [29] - The company ended the quarter with approximately $193 million in cash, cash equivalents, and investments, compared to $206 million at the end of 2024 [30] Business Line Data and Key Metrics Changes - Significant progress was made on the tau proteoform assay and broad scale proteome assay, with the tau assay exceeding targets for accuracy and reproducibility [12][14] - The assay demonstrated a median percent error of approximately 10%, significantly better than the target of less than 30% [15] - Reproducibility targets were also exceeded, with a median coefficient of variation (CV) of 1.5% across lanes, far better than the target of 20% [17] Market Data and Key Metrics Changes - There is significant interest from researchers in both targeted proteoform and broad scale discovery capabilities, with many expressing frustrations over current quantification methods [10] - The company conducted in-depth interviews with over 30 proteomics researchers to understand customer segments and drivers of adoption [9] Company Strategy and Development Direction - The company aims to unlock the full potential of the proteome, focusing on targeted proteoform detection and broad scale discovery [6] - Plans to launch a broad scale product in late 2026 are on track, with ongoing development efforts to reduce technical risks [6][29] - The company is exploring various partnership models, focusing on demonstrating the capabilities of their technology rather than immediate revenue generation [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming year, anticipating that 2025 will be pivotal for researchers utilizing the platform for tau-related studies [7] - The company is monitoring supply chain exposure to tariffs, indicating no current impact on sourcing materials [40] - Management emphasized the importance of customer feedback and ongoing research to refine their product offerings ahead of the commercial launch [62] Other Important Information - The company plans to submit a manuscript summarizing verification and validation work and biological pilot studies in the coming months [24] - A reduction in headcount by approximately 16% was implemented to extend the cash runway and focus on key development milestones [29] Q&A Session Summary Question: Update on Tau-related partnerships - Management confirmed ongoing discussions with potential partners in pharma and academia, expecting to sign an initial partnership in the first half of 2025 [36][37] Question: Supply chain exposure to tariffs - Management stated that they have not yet seen any effects on sourcing materials and have the ability to mitigate risks by sourcing from various locations, including the US [40][41] Question: Economics of targeted protein proteoform partnerships - Management indicated that they are exploring a range of business models for partnerships, focusing on demonstrating the technology's capabilities rather than immediate revenue [46][47] Question: Milestones for converting partnership interests - Management explained that the initial phase involves educating potential partners about the technology, with excitement noted across all customer segments, though the pace of engagement varies [55][56] Question: Potential blind spots impacting commercial launch - Management expressed confidence in their understanding of the work ahead and the importance of demonstrating capabilities to ensure a successful launch [58][61]

Financial Data and Key Metrics Changes - Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease from $21.6 million in Q1 2024, reflecting a focus on cost efficiency [28] - Research and development expenses decreased to $11.5 million from $12.9 million year-over-year [28] - General and administrative expenses were $7.3 million in Q1 2025 compared to $8.7 million in the prior year [29] - Overall net loss for Q1 2025 was $16.6 million, down from $18.7 million in the prior year [29] - Cash, cash equivalents, and investments at the end of the quarter totaled approximately $193 million, compared to $206 million at the end of 2024 [30] Business Line Data and Key Metrics Changes - The company is advancing its tau proteoform assay and broad scale proteome assay, with significant progress reported in transitioning these assays towards readiness for larger scale applications [11][12] - The tau proteoform assay exceeded expectations in reproducibility and accuracy, with a median percent error of approximately 10% and a median coefficient of variation of 1.5% [15][16] - The platform demonstrated a dynamic range exceeding four orders of magnitude, significantly better than current methods [19] Market Data and Key Metrics Changes - There is significant interest from customers and partners in the company's tau capabilities and targeted proteoform detection, with ongoing discussions with large pharma companies and academic institutions [9][10] - The company conducted in-depth interviews with over 30 proteomics researchers to understand customer segments and drivers of adoption, confirming strong interest in both targeted proteoform and broad scale discovery capabilities [8][9] Company Strategy and Development Direction - The company aims to unlock the full potential of the proteome, focusing on both targeted proteoform analysis and broad scale discovery as significant untapped opportunities in biology [27] - The anticipated launch of the platform is planned for late 2026, with a focus on ensuring cash runway extends well beyond that point [29][30] - The company is prioritizing partnerships that demonstrate the capabilities of measuring complete intact protein proteoforms at single molecule resolution [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made towards the launch of the platform and the positive feedback received from potential customers and partners [10][32] - The company is monitoring supply chain exposure closely, particularly regarding tariffs, but has not yet seen any significant impact on sourcing materials [40][41] - Management emphasized the importance of customer research and understanding market requirements to ensure a successful commercial launch [60][61] Other Important Information - The company reduced its headcount by approximately 16% to extend its cash runway and focus resources on key development milestones [29] - The verification and validation process for the tau assay was crucial for building confidence in the entire platform, as it shares core components with the broad scale proteome assay [58] Q&A Session Summary Question: Update on tau-related partnerships - Management confirmed ongoing discussions with partners in both pharma and academic sectors, expecting to sign an initial partnership in the first half of 2025 [36] Question: Supply chain exposure to tariffs - Management stated that they are monitoring the situation closely and have not yet seen any effects on sourcing materials or prices [40] Question: Economics of targeted protein proteoform partnerships - Management indicated that they are exploring a range of business models for partnerships, focusing on demonstrating the technology's capabilities rather than immediate revenue [44][46] Question: Milestones for converting partnership interests - Management explained that the initial phase involves educating potential partners about the technology, with excitement noted across all customer segments [52] Question: Potential blind spots impacting commercial launch - Management expressed confidence in their understanding of the work ahead and the importance of product reliability and market positioning for a successful launch [56][59]